Previous Section
Drug Therapy
1. Thalidomide in newly diagnosed multiple myeloma: influence of thalidomide treatment on peripheral blood stem cell collection yield.
- Author
- Breitkreutz I; Lokhorst HM; Raab MS; Holt BV; Cremer FW; Herrmann D; Glasmacher A; Schmidt-Wolf IG; Blau IW; Martin H; Salwender H; Haenel A; Sonneveld P; Goldschmidt H;
- Institution
- 1Department of Internal Medicine V, University of Heidelberg, Heidelberg, Germany.
- Journal
- Leukemia. 2007 Mar 22;.
- Abstract URL
- Click here to view abstract
2. The emerging role of targeted therapy for hematologic malignancies: update on bortezomib and tipifarnib.
- Author
- Armand JP; Burnett AK; Drach J; Harousseau JL; Lowenberg B; San Miguel J; Armand JP; Burnett AK; Drach J; Harousseau JL; Lowenberg B; San Miguel J;
- Institution
- Institut Gustave-Roussy, Dept. of Medicine, 39 Rue Camille-Desmoulins, Villejuif Cedex 94805, France. armand.jean-pierre@claudiusregaud.fr
- Journal
- Oncologist. 2007 Mar;12(3):281-90.
- Abstract URL
- Click here to view abstract
3. A different schedule of zoledronic acid can reduce the risk of the osteonecrosis of the jaw in patients with multiple myeloma.
- Author
- Corso A; Varettoni M; Zappasodi P; Klersy C; Mangiacavalli S; Pica G; Lazzarino M;
- Institution
- 1Institute of Hematology, Fondazione IRCCS Policlinico San Matteo, University of Pavia, Pavia, Italy.
- Journal
- Leukemia. 2007 Apr 5;.
- Abstract URL
- Click here to view abstract
4. Community experience with bortezomib in patients with multiple myeloma.
- Author
- Onitilo AA; Engel J; Olatosi B; Fagbemi S;
- Institution
- Department of Hematology/Oncology, Marshfield Clinic-Weston Center, Weston, Wisconsin.
- Journal
- Am J Hematol. 2007 Feb 14;.
- Abstract URL
- Click here to view abstract
5. Bisphosphonates and jaw osteonecrosis: the UAMS experience.
- Author
- Clarke BM; Boyette J; Vural E; Suen JY; Anaissie EJ; Stack BC Jr;
- Institution
- Department of Otolaryngology-Head and Neck Surgery, University of Arkansas for Medical Sciences, Little Rock, AR 72205, USA.
- Journal
- Otolaryngol Head Neck Surg. 2007 Mar;136(3):396-400.
- Abstract URL
- Click here to view abstract
6. Initial testing (stage 1) of the proteasome inhibitor bortezomib by the pediatric preclinical testing program.
- Author
- Houghton PJ; Morton CL; Kolb EA; Lock R; Carol H; Reynolds CP; Keshelava N; Maris JM; Keir ST; Wu J; Smith MA;
- Institution
- St. Jude Children's Research Hospital, Memphis, Tennessee.
- Journal
- Pediatr Blood Cancer. 2007 Apr 9;.
- Abstract URL
- Click here to view abstract
7. Monotherapy with low-dose thalidomide for relapsed or refractory multiple myeloma: better response rate with earlier treatment.
- Author
- Maisnar V; Radocha J; Buchler T; Blaha V; Maly J; Hajek R;
- Institution
- 2nd Department of Internal Medicine, Charles University Hospital, Sokolska, Hradec Kralove, Czech Republic. maisnar@fnhk.cz
- Journal
- Eur J Haematol. 2007 Oct;79(4):305-9. Epub 2007 Sep 4.
- Abstract URL
- Click here to view abstract
8. Complete response correlates with long-term survival and progression-free survival in high-dose therapy in multiple myeloma.
- Author
- van de Velde HJ; Liu X; Chen G; Cakana A; Deraedt W; Bayssas M;
- Institution
- Johnson & Johnson Parmaceutical Research & Development, Turnhoutseweg 30, 2340 Beerse, Belgium. hvdvelde@prdbe.jnj.com
- Journal
- Haematologica. 2007 Oct;92(10):1399-406.
- Abstract URL
- Click here to view abstract
9. Efficacy of single-agent bortezomib vs. single-agent thalidomide in patients with relapsed or refractory multiple myeloma: a systematic comparison.
- Author
- Prince HM; Adena M; Smith DK; Hertel J;
- Institution
- Department of Haematology and Medical Oncology, Peter MacCallum Cancer Centre and University of Melbourne, Melbourne, Vic., Australia.
- Journal
- Eur J Haematol. 2007 Aug;79(2):93-9. Epub 2007 Jun 28.
- Abstract URL
- Click here to view abstract
10. A practical guide to achieving and maintaining the best response to lenalidomide in multiple myeloma: roundtable proceedings.
- Author
- Stadtmauer EA; Lonial S; Vesole DH; Abonour R; Alsina M; Badros A; Comenzo R; Durie B; Giralt S; Hussein M; Jakubowiak A; Mehta J; Niesvizky R; Orlowski R; Siegel D; Singhal S; Vescio R; Wang M; Zangari M; Munshi NC;
- Institution
- Hematology/Oncology Division, University of Pennsylvania Health System, Abramson Cancer Center, University of Pennsylvania School of Medicine, Philadelphia, PA 19104, USA, edward.stadtmauer@uphs.upenn.edu.
- Journal
- Clin Adv Hematol Oncol. 2007 Oct;5(10 Suppl 15):7-19, quiz 21-2.
Next: Clinical Trials
